A Phase 2 interventional study of pemetrexed in Ovarian Cancer and Peritoneal Cancer, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2009-12-04.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pemetrexed in Ovarian Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Ovarian Neoplasms.
Among the 13 studies testing pemetrexed in Ovarian Neoplasms, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2004, is one of 8 in phase 2, and was the 6th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 13 studies testing pemetrexed in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9
First in 2004; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is close to the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 36 across the 12 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 9 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
29 studies in Ovarian Neoplasms by Eli Lilly and Company: 6 open now, 9 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, this one is the 22nd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2004, is one of 14 in phase 2, and was the 13th registered.
Eli Lilly and Company’s Ovarian Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing pemetrexed in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 29 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity. This medication will be given over 10 minutes and may be administered intravenously (IV), through a vein in your arm. Vitamin supplementation is a required part of this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed
900 mg/m2, intravenous (IV), every 21 days, until disease progression
Also known as: LY231514, Alimta
Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (up to 44 months)
Number of Participants With Adverse Events by Grade
Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.
Time frame: every 21-day cycle up to 5 year follow-up
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: time of initial response until documented tumor progression (up to 44 months)
Progression-Free Survival
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.
Time frame: baseline until documented tumor progression (up to 44 months)
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline until death from any cause up to 5-year follow-up
| Milestone | Pemetrexed |
|---|---|
| Started | 51 |
| Completed | 48 |
| Not completed | 3 |
| Withdrew: Entry criteria not met | 2 |
| Withdrew: Inevaluable (never treated) | 1 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.
| participants | Pemetrexed |
|---|---|
| Complete Response | 1 |
| Partial Response | 9 |
| Stable Disease | 17 |
| Progressive Disease | 18 |
| Inevaluable | 3 |
Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.
| participants | Pemetrexed |
|---|---|
| Leukopenia - Grade 1 | 11 |
| Leukopenia - Grade 2 | 13 |
| Leukopenia - Grade 3 | 11 |
| Leukopenia - Grade 4 | 1 |
| Thrombocytopenia - Grade 1 | 15 |
| Thrombocytopenia - Grade 2 | 5 |
| Thrombocytopenia - Grade 3 | 2 |
| Thrombocytopenia - Grade 4 | 4 |
| Neutropenia - Grade 1 | 9 |
| Neutropenia - Grade 2 | 6 |
| Neutropenia - Grade 3 | 11 |
| Neutropenia - Grade 4 | 9 |
| Anemia - Grade 1 | 14 |
| Anemia - Grade 2 | 17 |
| Anemia - Grade 3 | 7 |
| Anemia - Grade 4 | 0 |
| Transfusion - Grade 1 | 0 |
| Transfusion - Grade 2 | 1 |
| Transfusion - Grade 3 | 0 |
| Transfusion - Grade 4 | 0 |
| Coagulation - Grade 1 | 0 |
| Coagulation - Grade 2 | 1 |
| Coagulation - Grade 3 | 0 |
| Coagulation - Grade 4 | 0 |
| Gastrointestinal - Grade 1 | 14 |
| Gastrointestinal - Grade 2 | 14 |
| Gastrointestinal - Grade 3 | 4 |
| Gastrointestinal - Grade 4 | 0 |
| Nausea/vomiting - Grade 1 | 15 |
| Nausea/vomiting - Grade 2 | 7 |
| Nausea/vomiting - Grade 3 | 4 |
| Nausea/vomiting - Grade 4 | 0 |
| Genitourinary - Grade 1 | 4 |
| Genitourinary - Grade 2 | 0 |
| Genitourinary - Grade 3 | 2 |
| Genitourinary - Grade 4 | 0 |
| Hepatic - Grade 1 | 2 |
| Hepatic - Grade 2 | 2 |
| Hepatic - Grade 3 | 1 |
| Hepatic - Grade 4 | 0 |
| Alopecia - Grade 1 | 7 |
| Alopecia - Grade 2 | 5 |
| Dermatologic - Grade 1 | 10 |
| Dermatologic - Grade 2 | 10 |
| Dermatologic - Grade 3 | 3 |
| Dermatologic - Grade 4 | 0 |
| Neurologic - Grade 1 | 12 |
| Neurologic - Grade 2 | 1 |
| Neurologic - Grade 3 | 4 |
| Neurologic - Grade 4 | 1 |
| SGOT - Grade 1 | 9 |
| SGOT - Grade 2 | 4 |
| SGOT - Grade 3 | 0 |
| SGOT - Grade 4 | 0 |
| Alkaline phosphatase - Grade 1 | 3 |
| Alkaline phosphatase - Grade 2 | 3 |
| Alkaline phosphatase - Grade 3 | 0 |
| Alkaline phosphatase - Grade 4 | 0 |
| Ocular - Grade 1 | 2 |
| Ocular - Grade 2 | 3 |
| Ocular - Grade 3 | 1 |
| Ocular - Grade 4 | 0 |
| Hemorrhage - Grade 1 | 2 |
| Hemorrhage - Grade 2 | 0 |
| Hemorrhage - Grade 3 | 1 |
| Hemorrhage - Grade 4 | 0 |
| Pulmonary - Grade 1 | 4 |
| Pulmonary - Grade 2 | 1 |
| Pulmonary - Grade 3 | 0 |
| Pulmonary - Grade 4 | 0 |
| Lymphopenia - Grade 1 | 1 |
| Lymphopenia - Grade 2 | 0 |
| Lymphopenia - Grade 3 | 0 |
| Lymphopenia - Grade 4 | 0 |
| Constitutional - Grade 1 | 17 |
| Constitutional - Grade 2 | 14 |
| Constitutional - Grade 3 | 5 |
| Constitutional - Grade 4 | 2 |
| Metabolic - Grade 1 | 20 |
| Metabolic - Grade 2 | 9 |
| Metabolic - Grade 3 | 4 |
| Metabolic - Grade 4 | 0 |
| Cardiovascular - Grade 1 | 3 |
| Cardiovascular - Grade 2 | 0 |
| Cardiovascular - Grade 3 | 0 |
| Cardiovascular - Grade 4 | 0 |
| Pain - Grade 1 | 8 |
| Pain - Grade 2 | 6 |
| Pain - Grade 3 | 1 |
| Pain - Grade 4 | 1 |
| Infection - Grade 1 | 2 |
| Infection - Grade 2 | 5 |
| Infection - Grade 3 | 5 |
| Infection - Grade 4 | 0 |
| Auditory - Grade 1 | 0 |
| Auditory - Grade 2 | 2 |
| Auditory - Grade 3 | 1 |
| Auditory - Grade 4 | 0 |
| Lymphatics - Grade 1 | 4 |
| Lymphatics - Grade 2 | 1 |
| Lymphatics - Grade 3 | 0 |
| Lymphatics - Grade 4 | 1 |
| Endocrine - Grade 1 | 2 |
| Endocrine - Grade 2 | 0 |
| Endocrine - Grade 3 | 0 |
| Endocrine - Grade 4 | 0 |
| Allergy - Grade 1 | 0 |
| Allergy - Grade 2 | 1 |
| Allergy - Grade 3 | 0 |
| Allergy - Grade 4 | 0 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| months | Pemetrexed |
|---|---|
| Duration of Response | 8.4 (2.8 to 30.4) |
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.
| months | Pemetrexed |
|---|---|
| Progression-Free Survival | 3.0 (1.0 to 33.1) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| months | Pemetrexed |
|---|---|
| Overall Survival | 11.4 (1.6 to 34.4) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 12/48 (25%) | 47/48 (97.9%) |
| Event | Pemetrexed |
|---|---|
| VomitingGastrointestinal disorders | 3/48 |
| DehydrationMetabolism and nutrition disorders | 3/48 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/48 |
| NauseaGastrointestinal disorders | 2/48 |
| PyrexiaGeneral disorders | 2/48 |
| RashSkin and subcutaneous tissue disorders | 2/48 |
| UrticariaSkin and subcutaneous tissue disorders | 2/48 |
| AnaemiaBlood and lymphatic system disorders | 1/48 |
| NeutropeniaBlood and lymphatic system disorders | 1/48 |
| Event | Pemetrexed |
|---|---|
| AnemiaBlood and lymphatic system disorders | 38/48 |
| ConstitutionalGeneral disorders | 38/48 |
| LeukopeniaBlood and lymphatic system disorders | 36/48 |
| NeutropeniaBlood and lymphatic system disorders | 35/48 |
| MetabolicMetabolism and nutrition disorders | 33/48 |
| GastrointestinalGastrointestinal disorders | 32/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 26/48 |
| Nausea/vomitingGastrointestinal disorders | 26/48 |
| DermatologicSkin and subcutaneous tissue disorders | 23/48 |
| NeurologicNervous system disorders | 18/48 |
| Age, Customized(participants) | Pemetrexed |
|---|---|
| <40 years | 1 |
| 40-49 years | 6 |
| 50-59 years | 14 |
| 60-69 years | 14 |
| 70-79 years | 11 |
| >79 years | 2 |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 48 |
| Male | 0 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| United States | 48 |
| Cell Type(participants) | Pemetrexed |
|---|---|
| Serous | 34 |
| Clear Cell | 5 |
| Mixed Epithelial | 6 |
| Endometrioid | 1 |
| Adenocarcinoma, Unspecified | 1 |
| Undifferentiated Carcinoma | 1 |
| Gynecologic Oncology Group Performance Status(participants) | Pemetrexed |
|---|---|
| 0 - Fully active | 30 |
| 1 - Ambulatory, Restricted Strenuous Activity | 15 |
| 2 - Ambulatory, No Work Activities | 3 |
| Prior Chemotherapy(participants) | Pemetrexed |
|---|---|
| Yes | 48 |
| No | 0 |
| Prior Radiotherapy(participants) | Pemetrexed |
|---|---|
| Yes | 1 |
| No | 47 |
| Race/Ethnicity(participants) | Pemetrexed |
|---|---|
| White | 47 |
| Black | 1 |
1 further baseline measures are reported on the registry.
The record gives a start of Sep 2004, a primary completion of Oct 2007 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed